Mei Ri Jing Ji Xin Wen·2025-12-23 17:09Core Viewpoint - The announcement from Haohai Biological Technology indicates that the company's actual controller, Jiang Wei, has been penalized for insider trading, with a total fine and confiscation amounting to 19.34 million yuan. The company asserts that this matter is unrelated to its operations and will not significantly impact its business or financials [2][3]. Group 1: Regulatory Actions - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading, with a confiscation of illegal gains amounting to 4.71 million yuan and a fine of 14.63 million yuan, totaling 19.34 million yuan [2][3]. - The penalty is directed at Jiang Wei personally, and the company emphasizes that it is not involved in the matter, as Jiang does not participate in daily management [2][3]. Group 2: Company Background - Haohai Biological Technology was established in 2007 and listed on the Hong Kong Stock Exchange in 2015, later becoming the first company to be listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board in October 2019 [2][3]. - The company primarily engages in the production and sales of biopharmaceuticals, including medical sodium hyaluronate gel, epidermal growth factor, chitosan, collagen, artificial crystals, and ophthalmic implants [3]. Group 3: Financial Performance - For the first three quarters of 2025, Haohai Biological Technology reported total revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down over 10% [4]. - The net cash flow from operating activities for the same period was 377 million yuan, reflecting a decline of 12.45% year-on-year, attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [4]. Group 4: Capital Operations - Despite the investigation of its actual controller, Haohai Biological Technology continued its capital operations, announcing on November 9 that it plans to acquire the remaining 20% stake in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for 74 million yuan, which would result in the company holding 100% of the target company's equity [5].